Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03LRU
|
||||
| Former ID |
DCL000035
|
||||
| Drug Name |
Alvespimycin hydrochloride
|
||||
| Synonyms |
Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Ovarian cancer; Refractory hematological malignancies [ICD9: 140-229, 140-239, 183, 200-209; ICD10:C56, C81-C86] | Phase 1 | [521606] | ||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
Bristol-Myers Squibb; Kosan Biosci.
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C32H49ClN4O8
|
||||
| Canonical SMILES |
CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)NC<br />CN(C)C)C)OC)OC(=O)N)C)C)O)OC.Cl
|
||||
| InChI |
1S/C32H48N4O8.ClH/c1-18-14-22-27(34-12-13-36(5)6)24(37)17-23(29(22)39)35-31(40)19(2)10-9-11-25(42-7)30(44-32(33)41)21(4)16-20(3)28(38)26(15-18)43-8;/h9-11,16-18,20,25-26,28,30,34,38H,12-15H2,1-8H3,(H2,33,41)(H,35,40);1H/b11-9-,19-10+,21-16+;/t18-,20+,25+,26+,28-,30+;/m1./s1
|
||||
| InChIKey |
DFSYBWLNYPEFJK-IHLRWNDRSA-N
|
||||
| CAS Number |
CAS 467214-21-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Heat shock protein HSP 90 | Target Info | Inhibitor | [536622], [536886], [537368] | |
| NetPath Pathway | IL2 Signaling Pathway | ||||
| TCR Signaling Pathway | |||||
| Pathway Interaction Database | Signaling events mediated by HDAC Class II | ||||
| Validated targets of C-MYC transcriptional activation | |||||
| Integrin-linked kinase signaling | |||||
| LKB1 signaling events | |||||
| Regulation of Telomerase | |||||
| Glucocorticoid receptor regulatory network | |||||
| Class I PI3K signaling events | |||||
| IL2 signaling events mediated by PI3K | |||||
| Regulation of Androgen receptor activity | |||||
| Integrins in angiogenesis | |||||
| Hypoxic and oxygen homeostasis regulation of HIF-1-alpha | |||||
| ErbB receptor signaling network | |||||
| VEGFR1 specific signals | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Class I PI3K signaling events mediated by Akt | |||||
| Reactome | Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | ||||
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | |||||
| Regulation of actin dynamics for phagocytic cup formation | |||||
| eNOS activation | |||||
| Regulation of PLK1 Activity at G2/M Transition | |||||
| Attenuation phase | |||||
| HSF1-dependent transactivation | |||||
| Loss of Nlp from mitotic centrosomes | |||||
| Recruitment of mitotic centrosome proteins and complexes | |||||
| Loss of proteins required for interphase microtubule organization?from the centrosome | |||||
| EPHA-mediated growth cone collapse | |||||
| VEGFA-VEGFR2 Pathway | |||||
| VEGFR2 mediated vascular permeability | |||||
| Anchoring of the basal body to the plasma membrane | |||||
| Constitutive Signaling by EGFRvIII | |||||
| WikiPathways | NRF2 pathway | ||||
| Nuclear Receptors Meta-Pathway | |||||
| Aryl Hydrocarbon Receptor Pathway | |||||
| Binding and Uptake of Ligands by Scavenger Receptors | |||||
| Signaling by ERBB2 | |||||
| Fcgamma receptor (FCGR) dependent phagocytosis | |||||
| Influenza Life Cycle | |||||
| EBV LMP1 signaling | |||||
| Aryl Hydrocarbon Receptor | |||||
| Corticotropin-releasing hormone | |||||
| TNF alpha Signaling Pathway | |||||
| Arylhydrocarbon receptor (AhR) signaling pathway | |||||
| Signaling by EGFR | |||||
| Semaphorin interactions | |||||
| Mitotic G2-G2/M phases | |||||
| Metabolism of nitric oxide | |||||
| NOD pathway | |||||
| References | |||||
| Ref 536622 | Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jul;51(1):34-41. | ||||
| Ref 536886 | Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82. | ||||
| Ref 537368 | Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells. Cancer Lett. 2009 May 20. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.